Effect of whey protein and dietary fiber on appetite and weight management

The effect of biscuit fortified with whey protein and dietary fiber on biochemical and behavioral factors of appetite, anthropometric indices, and glycemic profile in overweight or obese adults

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180509039596N2

Enrollment

Registered

2018-06-25

Start date

2018-06-22

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and obesity. Overweight and obesity

Interventions

Intervention 1: Intervention group: Whey protein and dietary fiber enriched biscuits. Biscuits will be consumed during 60 days of intervention duration. Participants will take 14 grams pre day whey pr

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Male and female gender Age 20 -50 years old BMI higher than 25 kg/m2

Exclusion criteria

Exclusion criteria: Follow weight loss diet during 6 months ago Psychological disorders related to eating disorders Use of multivitamin-mineral supplements and herbal medications Chronic disease and use drugs, which affected the metabolism, body composition and appetite Food allergy Pregnancy and lactation Alcohol and tobacco use

Design outcomes

Primary

Measure	Time frame
Energy intake and appetite. Timepoint: Baseline, 14, 28, 42, and 60 days after intervention. Method of measurement: Food record questionnaire, and appetite assessment questionnaire.	—

Secondary

Measure	Time frame
Ghrelin. Timepoint: Baseline and end of intervention. Method of measurement: Elisa kit.;Leptin. Timepoint: Baseline and end of intervention. Method of measurement: Elisa kit.;Serotonin. Timepoint: Baseline and end of intervention. Method of measurement: Elisa kit.;Glucagon-like peptide-1 (GLP-1). Timepoint: Baseline and end of intervention. Method of measurement: Elisa kit.;Fasting blood glucose. Timepoint: Baseline and end of intervention. Method of measurement: Auto Analyzer Biochemistry.;Insulin. Timepoint: Baseline and end of intervention. Method of measurement: Elisa kit.;Blood lipids including total cholesterol, low density lipoprotein, high density lipoprotein, and triglyceride. Timepoint: Baseline and end of intervention. Method of measurement: Auto Analyzer Biochemistry.;Body weight. Timepoint: Baseline and end of intervention. Method of measurement: weight scale.;Waist circumeference. Timepoint: Baseline and end of intervention. Method of measurement: Strip meter.;Waist to height ratio. Timepoint: Baseline and end of intervention. Method of measurement: Strip meter.;Fat mass percentage. Timepoint: Baseline and end of intervention. Method of measurement: Bioelectrical impedance analysis (BIA).;Mood indices. Timepoint: Baseline and end of intervention. Method of measurement: Emotionality Activity Sociability (EAS) questionnaire.;Quality of Life. Timepoint: Baseline and end of intervention. Method of measurement: Quality of Life questionnaire.;Body mass index. Timepoint: Baseline and end of intervention. Method of measurement: Weight scale and strip meter.;Fat free mass. Timepoint: Baseline and end of intervention. Method of measurement: Bioelectrical impedance analysis (BIA).	—

Measure

Time frame

Ghrelin. Timepoint: Baseline and end of intervention. Method of measurement: Elisa kit.;Leptin. Timepoint: Baseline and end of intervention. Method of measurement: Elisa kit.;Serotonin. Timepoint: Baseline and end of intervention. Method of measurement: Elisa kit.;Glucagon-like peptide-1 (GLP-1). Timepoint: Baseline and end of intervention. Method of measurement: Elisa kit.;Fasting blood glucose. Timepoint: Baseline and end of intervention. Method of measurement: Auto Analyzer Biochemistry.;Insulin. Timepoint: Baseline and end of intervention. Method of measurement: Elisa kit.;Blood lipids including total cholesterol, low density lipoprotein, high density lipoprotein, and triglyceride. Timepoint: Baseline and end of intervention. Method of measurement: Auto Analyzer Biochemistry.;Body weight. Timepoint: Baseline and end of intervention. Method of measurement: weight scale.;Waist circumeference. Timepoint: Baseline and end of intervention. Method of measurement: Strip meter.;Waist to height ratio. Timepoint: Baseline and end of intervention. Method of measurement: Strip meter.;Fat mass percentage. Timepoint: Baseline and end of intervention. Method of measurement: Bioelectrical impedance analysis (BIA).;Mood indices. Timepoint: Baseline and end of intervention. Method of measurement: Emotionality Activity Sociability (EAS) questionnaire.;Quality of Life. Timepoint: Baseline and end of intervention. Method of measurement: Quality of Life questionnaire.;Body mass index. Timepoint: Baseline and end of intervention. Method of measurement: Weight scale and strip meter.;Fat free mass. Timepoint: Baseline and end of intervention. Method of measurement: Bioelectrical impedance analysis (BIA).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Hassanzadeh-Rostami

Shiraz University of Medical Sciences

Hassanzadeh_z8@yahoo.com+98 71 3725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026